Numans Health Food Holdings Company Limited (Stock Code: 2530) announced an acquisition of 3,000,000 XtalPi shares (Stock Code: 2228) on February 5, 2026, at a total consideration of approximately HK$33.8 million. The average purchase price was about HK$11.28 per share, with the transaction funded entirely by the internal resources of Numans Health Food Holdings Company Limited.

The acquired shares were obtained on the open market, and the transaction constituted a discloseable transaction under Chapter 14 of the Listing Rules. Numans Health Food Holdings Company Limited had previously acquired a total of 7,000,000 XtalPi shares on January 5, 2026, January 27, 2026, and January 28, 2026 for around HK$84.6 million. According to Rule 14.22 of the Listing Rules, these acquisitions must be aggregated, and they collectively remain within the threshold of a discloseable transaction.

XtalPi’s operations involve a quantum physics-based, AI-powered, and robotics-driven R&D platform that collaborates with various global biotech and pharmaceutical clients. The published financial information of XtalPi shows revenue of RMB517,076,000 for the six months ended June 30, 2025, while total assets and net assets (liabilities) as of June 30, 2025, were RMB7,718,140,000 and RMB7,028,666,000 respectively.

Numans Health Food Holdings Company Limited is principally engaged in marketing, sales, and distribution of finished nutritional products in mainland China. The company pursued the acquisition to enhance returns on surplus cash reserves and expressed a positive outlook on XtalPi’s market presence in drug discovery solutions.